tiprankstipranks
Trending News
More News >
Spire Healthcare Group PLC (GB:SPI)
LSE:SPI

Spire Healthcare (SPI) AI Stock Analysis

Compare
52 Followers

Top Page

GB

Spire Healthcare

(LSE:SPI)

Rating:72Outperform
Price Target:
233.00p
▲(4.25%Upside)
Spire Healthcare's strong financial performance and positive technical indicators are the main strengths, supported by favorable corporate events. However, the high valuation poses a risk, suggesting a need for cautious optimism.

Spire Healthcare (SPI) vs. iShares MSCI United Kingdom ETF (EWC)

Spire Healthcare Business Overview & Revenue Model

Company DescriptionSpire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments. The company also provides eye surgery and treatments, family planning, gastroenterology, general medicine, general surgery, haematology, hand surgery, hip and knee treatment, and heart and kidney treatments. In addition, it offers treatments in the areas of men's health, neurosurgery and neurology, paediatrics, pain management, rehabilitation, sports, physiotherapy, podiatry, respiratory care, and rheumatology; and scans and investigations, skin treatments, spinal care, sports science, urology care, vascular surgery, weight loss, and women's health. Further, the company offers various tests and scans, which include cardiac CT, CT, MRI, ultrasound, and X-ray scans. It offers diagnostics, in-patient, daycase, and out-patient care services through 40 hospitals and eight clinics across England, Wales, and Scotland. Spire Healthcare Group plc was founded in 2007 and is headquartered in London, the United Kingdom.
How the Company Makes MoneySpire Healthcare generates revenue primarily through the provision of private healthcare services. The company earns income from patients who pay for treatments directly, as well as through partnerships with private medical insurers who cover healthcare costs for their policyholders. In addition, Spire Healthcare receives revenue from the National Health Service (NHS) by providing certain medical services under contracts. Key revenue streams include surgical procedures, diagnostic services, consultations, and outpatient treatments. The company's financial performance is influenced by factors such as patient volume, service mix, pricing strategies, and its ability to maintain strong relationships with insurers and the NHS.

Spire Healthcare Financial Statement Overview

Summary
Spire Healthcare shows strong revenue growth and operational efficiency, with consistent improvements in gross and EBIT margins. However, the modest net profit margin and high leverage present challenges. The balance sheet indicates substantial leverage with a high debt-to-equity ratio, and cash flow generation is robust, supporting liquidity and investments.
Income Statement
75
Positive
Spire Healthcare has demonstrated consistent revenue growth over recent years, with a significant increase from £919.9M in 2020 to £1.51B in 2024. Gross profit margin improved to 45.23% in 2024, indicating strong cost management. However, the net profit margin remains modest at 1.68%, suggesting room for improvement in overall profitability. EBIT and EBITDA margins show stable operational efficiency, with the latter at 14.06% in 2024.
Balance Sheet
65
Positive
The company maintains a relatively high debt-to-equity ratio of 1.71, reflecting substantial leverage. However, return on equity (ROE) is modest at 3.39%, indicating efficient use of equity. The equity ratio at 31.94% suggests a balanced capital structure, though increasing equity could mitigate leverage risks.
Cash Flow
70
Positive
Spire Healthcare's cash flow from operations has shown a positive trend, reaching £235.7M in 2024, supporting its capital expenditures and free cash flow generation. Free cash flow growth is steady, though the operating to net income ratio of 9.28 indicates reliance on operating performance for cash generation.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.51B1.36B1.20B1.11B919.90M
Gross Profit683.60M520.60M440.50M394.10M361.80M
EBITDA250.40M231.20M202.10M182.20M-51.90M
Net Income25.40M27.30M8.60M-9.70M-233.90M
Balance Sheet
Total Assets2.34B2.29B2.16B2.24B2.10B
Cash, Cash Equivalents and Short-Term Investments43.70M49.60M74.20M202.60M106.30M
Total Debt1.28B1.26B1.19B1.27B1.17B
Total Liabilities1.60B1.55B1.43B1.53B1.40B
Stockholders Equity748.40M739.90M731.00M709.60M706.60M
Cash Flow
Free Cash Flow123.60M115.50M72.80M101.30M95.10M
Operating Cash Flow235.70M199.90M160.50M170.60M141.70M
Investing Cash Flow-99.00M-157.20M-98.00M-48.30M-46.40M
Financing Cash Flow-145.10M-82.90M-190.90M-26.00M-79.80M

Spire Healthcare Technical Analysis

Technical Analysis Sentiment
Positive
Last Price223.50
Price Trends
50DMA
201.65
Positive
100DMA
198.27
Positive
200DMA
210.92
Positive
Market Momentum
MACD
6.71
Negative
RSI
69.99
Neutral
STOCH
87.96
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SPI, the sentiment is Positive. The current price of 223.5 is above the 20-day moving average (MA) of 213.60, above the 50-day MA of 201.65, and above the 200-day MA of 210.92, indicating a bullish trend. The MACD of 6.71 indicates Negative momentum. The RSI at 69.99 is Neutral, neither overbought nor oversold. The STOCH value of 87.96 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:SPI.

Spire Healthcare Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
GBSPI
72
Outperform
£913.38M36.033.41%1.01%11.20%-6.80%
GBCRW
71
Outperform
£763.42M65.434.50%2.46%6.74%54.83%
GBAMS
66
Neutral
£453.06M63.442.93%1.04%40.66%-55.09%
60
Neutral
HK$15.27B5.80-7.43%4.22%11.60%-21.06%
GBAPH
59
Neutral
$355.92M-5.04%-1.02%67.70%
55
Neutral
£302.72M7.7511.74%38.80%
GBTLY
53
Neutral
£471.71K-3.66%-23.61%-30.61%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:SPI
Spire Healthcare
227.00
-11.19
-4.70%
GB:AMS
Advanced Medical Solutions
209.00
-13.74
-6.17%
GB:APH
Alliance Pharma
64.70
27.10
72.07%
GB:CRW
Craneware
2,200.00
-146.73
-6.25%
GB:PRTC
PureTech Health
129.40
-57.40
-30.73%
GB:TLY
Totally
0.24
-7.26
-96.80%

Spire Healthcare Corporate Events

Other
Spire Healthcare Directors Exercise Sharesave Plan Options
Positive
Jun 24, 2025

Spire Healthcare Group PLC announced that its Executive Directors, Justin Ash and Harbant Samra, have exercised their options under the 2022 Sharesave Plan, acquiring 1,818 shares each at an exercise price of £1.98 per share. This transaction reflects the directors’ continued confidence in the company’s growth and stability, as all acquired shares have been retained, potentially strengthening their alignment with shareholder interests.

The most recent analyst rating on (GB:SPI) stock is a Buy with a £2.90 price target. To see the full list of analyst forecasts on Spire Healthcare stock, see the GB:SPI Stock Forecast page.

Business Operations and StrategyRegulatory Filings and Compliance
Spire Healthcare Announces Change in Voting Rights
Neutral
Jun 23, 2025

Spire Healthcare Group PLC has announced a change in its voting rights, with Bridgemere Securities Limited increasing its stake to 5.5705% from a previous 4.0900%. This adjustment in voting rights could potentially impact the company’s governance and decision-making processes, influencing its strategic direction and stakeholder interests.

The most recent analyst rating on (GB:SPI) stock is a Buy with a £321.00 price target. To see the full list of analyst forecasts on Spire Healthcare stock, see the GB:SPI Stock Forecast page.

Executive/Board Changes
Spire Healthcare Announces New Executive LTIP Awards
Neutral
Jun 19, 2025

Spire Healthcare Group PLC has announced the grant of additional performance share awards under its Long Term Incentive Plan (LTIP) to Executive Director Harbant Samra. The awards, reflecting a recent change in his base salary, are set at 200% of his current salary and will vest based on performance conditions related to shareholder return, ROCE, hospital EBIT margin, and operational excellence. This move aligns with the company’s shareholder-approved Remuneration Policy and underscores its commitment to incentivizing leadership performance.

The most recent analyst rating on (GB:SPI) stock is a Buy with a £321.00 price target. To see the full list of analyst forecasts on Spire Healthcare stock, see the GB:SPI Stock Forecast page.

Regulatory Filings and Compliance
Spire Healthcare Announces Change in Major Holdings
Neutral
Jun 4, 2025

Spire Healthcare Group PLC has announced a change in its major holdings, with FIL Limited acquiring or disposing of voting rights and financial instruments. The transaction resulted in FIL Limited holding 9.105% of the voting rights in Spire Healthcare. This change in holdings could impact the company’s governance and influence decision-making processes, potentially affecting stakeholders and market perceptions.

The most recent analyst rating on (GB:SPI) stock is a Buy with a £321.00 price target. To see the full list of analyst forecasts on Spire Healthcare stock, see the GB:SPI Stock Forecast page.

Shareholder Meetings
Spire Healthcare’s 2025 AGM Resolutions Passed with Strong Support
Positive
May 14, 2025

Spire Healthcare Group PLC announced the successful passage of all resolutions at its 2025 Annual General Meeting, held on May 14, 2025. The results indicate strong shareholder support, with most resolutions receiving near-unanimous approval. This outcome reflects positively on the company’s governance and may enhance its position in the healthcare sector, potentially influencing investor confidence and future strategic decisions.

The most recent analyst rating on (GB:SPI) stock is a Buy with a £321.00 price target. To see the full list of analyst forecasts on Spire Healthcare stock, see the GB:SPI Stock Forecast page.

Business Operations and StrategyFinancial Disclosures
Spire Healthcare Reports Steady Performance and Strategic NHS Partnership
Positive
May 14, 2025

Spire Healthcare Group PLC reported that its performance from January to April 2025 aligned with expectations and the 2025 guidance, with a transformation program on track to deliver significant efficiencies. The company, which has full UK revenue exposure, does not foresee any major cost or supply chain issues due to recent tariff announcements. Additionally, Spire Healthcare has been named a founding supplier in the Government’s National Strategic Supplier Relationship programme, enhancing its collaboration with the NHS for sustainable NHS commissioning.

The most recent analyst rating on (GB:SPI) stock is a Buy with a £321.00 price target. To see the full list of analyst forecasts on Spire Healthcare stock, see the GB:SPI Stock Forecast page.

Business Operations and Strategy
Spire Healthcare Executives Exercise Share Awards, Retain Shares
Positive
Apr 10, 2025

Spire Healthcare Group PLC announced that its Executive Directors, Justin Ash and Harbant Samra, have exercised their vested Executive Share Plan awards. Justin Ash exercised both his Long Term Incentive Plan and Deferred Share Bonus Plan awards, retaining a significant number of shares after tax satisfaction, while Harbant Samra exercised his Long Term Incentive Plan award, also retaining shares. This move reflects the directors’ confidence in the company’s future and their commitment to its growth, potentially impacting stakeholder perceptions positively.

Shareholder MeetingsFinancial Disclosures
Spire Healthcare Releases 2024 Annual Report and Announces 2025 AGM
Positive
Apr 8, 2025

Spire Healthcare Group plc has published its 2024 Annual Report and 2025 Notice of Annual General Meeting, with documents available on its website and the National Storage Mechanism. The company encourages shareholders to attend the AGM on 14 May 2025 in London and submit questions via email, with resolutions and voting results to be shared post-meeting. This announcement underscores Spire Healthcare’s commitment to transparency and shareholder engagement, potentially strengthening its market position and stakeholder trust.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 24, 2025